DDInter624 DDInter1678
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sirolimus
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Efavirenz {u} (Compound) causes {v} (Side Effect) Glycosuria
Glycosuria {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Efavirenz {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Efavirenz {u} (Compound) causes {v} (Side Effect) Glycosuria
Glycosuria {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Efavirenz {u} (Compound) causes {v} (Side Effect) Bone pain
Bone pain {u} (Side Effect) is caused by {v} (Compound) Estradiol
Estradiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) downregulates {v} (Gene) SATB1
SATB1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sirolimus (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Sirolimus (Compound)
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Sirolimus (Compound)
Efavirenz (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Sirolimus (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Sirolimus (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)
Efavirenz (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)
Efavirenz (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Efavirenz (Compound) causes Bone pain (Side Effect) and Bone pain (Side Effect) is caused by Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) downregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Sirolimus (Compound)